证券代码：300642 证券简称：透景生命 公告编号：2025-067 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、经上海透景生命科技股份有限公司（以下简称"公司"）全体董事一致 同意豁免会议通知时间要求，公司第四届董事会第十三次（临时）会议（以下简 称"本次会议"）通知于 2025 年 09 月 29 日通过口头或专人送达的方式通知公 司全体董事。 2、本次会议于 2025 年 09 月 30 日在上海市浦东新区汇庆路 412 号公司会议 室以通讯会议的方式召开。 上海透景生命科技股份有限公司 关于第四届董事会第十三次会议决议的公告 具体内容请详见中国证券监督管理委员会指定的信息披露媒体巨潮资讯网 （http://www.cninfo.com.cn）同期披露的相关公告。 表决结果：7 名同意，占出席会议的董事人数的 100%；0 名弃权；0 名反对。 三、备查文件 1、公司第四届董事会第十三次会议决议。 3、本次会议应出席董事 7 名，实际参加会议的董事 7 名，其中独立董事 3 名。 4、本次会议由公司董事长姚见儿先生召集并 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to price reductions in tumor marker detection products and decreased demand for high-end tumor testing [1][2]. Financial Performance - For H1 2025, the company achieved operating revenue of 159 million yuan, a decrease of 26.25% year-on-year, and a net profit attributable to shareholders of 3 million yuan, down 58.41% [1]. - In Q2 2025, operating revenue was 84 million yuan, a decline of 31.35%, with a net profit of 2 million yuan, down 79.43% [1]. Revenue Sources - The main revenue source, reagent sales, amounted to 147 million yuan in H1 2025, reflecting a year-on-year decrease of 27.48% due to industry policy adjustments and reduced market demand for high-end tumor testing [2]. - The sales prices of tumor marker detection products and HPV testing products have decreased compared to the same period last year [2]. R&D and Product Development - The company maintains a high R&D expenditure rate of around 15%, with 70 ongoing projects across various technology platforms, including PCR and mass spectrometry [3]. - In H1 2025, the company obtained 2 new invention patents and completed the installation of 121 units of various instruments, indicating a significant improvement in installation speed compared to previous years [3]. Strategic Acquisitions - The company has completed the integration of its subsidiary, Hebei Toukeng, focusing on invasive fungal disease detection, thereby entering a new market segment [3]. - In August, the company announced plans to acquire Kanglu Bio, a leader in the pathology diagnosis field, which will enhance its capabilities in molecular pathology technologies [4]. Future Outlook - The company expects net profits for 2025, 2026, and 2027 to be 9 million, 13 million, and 17 million yuan, respectively, with corresponding PE ratios of 444, 293, and 224 [4]. - A DCF model estimates the company's overall valuation at 5 billion yuan, with a target price of approximately 31 yuan per share, maintaining a "recommend" rating [4].

Group 1 - The core viewpoint of the news is that Tongjing Life has seen a stock price increase of 5.03%, reaching 23.18 CNY per share, with a trading volume of 136 million CNY and a turnover rate of 4.41%, resulting in a total market capitalization of 3.768 billion CNY [1] - Tongjing Life, established on November 6, 2003, and listed on April 21, 2017, specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1] - The revenue composition of Tongjing Life is as follows: 92.50% from reagents, 6.20% from instruments, 1.26% from services, and 0.04% from materials [1] Group 2 - Citic Prudential Fund's multi-strategy mixed fund (LOF) A (165531) has entered the top ten circulating shareholders of Tongjing Life, holding 1.2039 million shares, which is 0.87% of the circulating shares, with an estimated floating profit of approximately 1.3363 million CNY [2] - The fund was established on June 16, 2017, with a latest scale of 1.245 billion CNY, achieving a year-to-date return of 39.46%, ranking 2133 out of 8167 in its category, and a one-year return of 62.73%, ranking 1279 out of 8010 [2] Group 3 - The fund managers of Citic Prudential multi-strategy mixed fund (LOF) A are Jiang Feng and Wang Ying, with Jiang Feng having a tenure of 5 years and 171 days and a total fund asset scale of 5.782 billion CNY, achieving a best fund return of 123.41% during his tenure [3] - Wang Ying has a tenure of 8 years and 229 days with a total fund asset scale of 6.176 billion CNY, achieving a best fund return of 54.3% during her tenure [3]

证券代码：300642 证券简称：透景生命 公告编号：2025-065 上海透景生命科技股份有限公司 关于收购武汉康录生物技术股份有限公司控股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、交易的进展情况 截至本公告披露日，本次交易各方已根据《关于武汉康录生物技术股份有限 公司之股份转让协议》的约定完成了 2025 年股份转让的交割工作，具体情况如 下： 1、截至 2025 年 08 月 29 日，康录生物已针对 2025 年整体股份转让事宜在 武汉股权托管交易中心完成了股份变更登记，并按协议约定出具了有效的出资证 明书，公司已被登记为持有康录生物 7,923,879 股股份（占其股份总数的 72.8630%） 的股东；同时，根据协议约定，康录生物已在武汉市市场监督管理局办理完毕 2025 年整体股份转让的工商变更登记，包括但不限于新换发的营业执照、董事 会成员及监事人员的登记备案等；根据公司与各方签署的股份转让协议的约定， 公司已于近日完成向陈刚、谢俊、苏州工业园区新建元二期创业投资企业（有限 合伙）等 17 名交易对手方支付了全部的 20 ...

Market Overview - On September 17, the medical device sector experienced a decline of 0.22%, with Toujing Life leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Notable gainers in the medical device sector included: - Hualan Biological (301093) with a closing price of 39.01, up 5.20% and a trading volume of 85,900 shares, totaling a transaction value of 330 million yuan [1] - Xinhua Medical (600587) closed at 17.16, up 5.08% with a trading volume of 451,500 shares, totaling 767 million yuan [1] - Haooubo (688656) closed at 168.52, up 5.00% with a trading volume of 16,600 shares, totaling 272 million yuan [1] - Conversely, the following companies saw significant declines: - Toujing Life (300642) closed at 24.55, down 7.53% with a trading volume of 168,900 shares, totaling 426 million yuan [2] - Jimin Health (603222) closed at 13.22, down 4.06% with a trading volume of 748,900 shares, totaling 995 million yuan [2] - Meihua Medical (301363) closed at 27.31, down 2.95% with a trading volume of 153,300 shares, totaling 422 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 894 million yuan from institutional investors, while retail investors contributed a net inflow of 818 million yuan [2] - Notable capital flows included: - Haooubo (688656) with a net inflow of 39.06 million yuan from institutional investors, but a net outflow of 23.69 million yuan from speculative funds [3] - Xinhua Medical (600587) had a net inflow of 38.89 million yuan from institutional investors, with a net outflow of 64.90 million yuan from speculative funds [3] - Hualan Biological (301093) recorded a net inflow of 24.68 million yuan from institutional investors, while retail investors saw a net outflow of 25.99 million yuan [3]

Company Overview - Shanghai TuoJing Life Technology Co., Ltd. is located at 412 Huiqing Road, Pudong New District, Shanghai, established on November 6, 2003, and listed on April 21, 2017 [1] - The company specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1] Financial Performance - As of the latest report, TuoJing Life's stock price is 25.20 CNY per share, with a trading volume of 205 million CNY and a turnover rate of 5.80%, resulting in a total market capitalization of 4.096 billion CNY [1] - The revenue composition of the company is as follows: 92.50% from reagents, 6.20% from instruments, 1.26% from services, and 0.04% from materials [1] Shareholder Information - CITIC Prudential Fund's multi-strategy mixed fund (LOF) A (165531) entered the top ten circulating shareholders of TuoJing Life in the second quarter, holding 1.2039 million shares, which accounts for 0.87% of the circulating shares [2] - The estimated floating loss for this fund today is approximately 1.6253 million CNY [2] Fund Manager Performance - The fund manager Jiang Feng has a tenure of 5 years and 158 days, with a total fund asset size of 5.782 billion CNY, achieving a best fund return of 125.62% during his tenure [3] - The other fund manager Wang Ying has a tenure of 8 years and 216 days, managing assets of 3.835 billion CNY, with a best fund return of 51.4% during her tenure [3]

Core Viewpoint - The stock of TuoJing Life has experienced significant fluctuations, with a year-to-date increase of 88.23%, indicating strong market interest despite recent declines in share price and financial performance [1][2]. Financial Performance - For the first half of 2025, TuoJing Life reported revenue of 159 million yuan, a year-on-year decrease of 26.25%, and a net profit attributable to shareholders of 2.76 million yuan, down 58.41% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 264 million yuan, with 81.36 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 16, TuoJing Life's stock price was 26.30 yuan per share, with a market capitalization of 4.275 billion yuan. The stock has seen a trading volume of 96.61 million yuan and a turnover rate of 2.63% [1]. - The stock has experienced a net outflow of 2.24 million yuan in principal funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for TuoJing Life was 16,000, a decrease of 6.19% from the previous period, while the average number of circulating shares per person increased by 6.60% to 8,614 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A is a new entrant, holding 1.20 million shares [3]. Business Overview - TuoJing Life, established on November 6, 2003, and listed on April 21, 2017, specializes in the research, production, and sales of in vitro diagnostic products, with 92.50% of its revenue coming from reagent sales [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics [1].

Market Overview - On September 12, the medical device sector declined by 0.72%, with Shanwaishan leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Top Gainers in Medical Device Sector - Haobobo (688656) closed at 173.11, up 18.16% with a trading volume of 21,900 lots and a transaction value of 333 million [1] - Tianchen Medical (688013) closed at 67.57, up 11.10% with a trading volume of 30,800 lots and a transaction value of 197 million [1] - Toukeng Life (300642) closed at 27.41, up 10.39% with a trading volume of 185,700 lots and a transaction value of 482 million [1] - Zhend Medical (603301) closed at 35.64, up 10.00% with a trading volume of 64,400 lots and a transaction value of 228 million [1] Top Losers in Medical Device Sector - Shanwaishan (688410) closed at 15.35, down 4.78% with a trading volume of 142,500 lots and a transaction value of 216 million [2] - Aojing Medical (688613) closed at 26.03, down 3.38% with a trading volume of 77,200 lots and a transaction value of 202 million [2] - Jiming Health (603222) closed at 13.66, down 2.84% with a trading volume of 1,008,500 lots and a transaction value of 1.382 billion [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 199 million from institutional investors, while retail investors saw a net inflow of 256 million [2] - Retail investors had a net outflow of 57.41 million [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 127 million from institutional investors, while retail investors experienced a net outflow of 11.9 million [3] - Toukeng Life (300642) saw a net inflow of 56.51 million from institutional investors, with a net outflow of 5.40 million from retail investors [3] - Meihua Medical (301363) had a net inflow of 31.17 million from institutional investors, while retail investors had a net outflow of 1.08 million [3]

Company Overview - Shanghai TuoJing Life Technology Co., Ltd. is located at 412 Huiqing Road, Pudong New District, Shanghai, established on November 6, 2003, and listed on April 21, 2017. The company specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1]. Business Performance - The main revenue composition of the company includes: 92.50% from reagent sales, 6.20% from instrument sales, 1.26% from services, and 0.04% from materials [1]. - As of September 12, the stock price increased by 5.03%, reaching 26.08 CNY per share, with a trading volume of 221 million CNY and a turnover rate of 6.43%, resulting in a total market capitalization of 4.239 billion CNY [1]. Shareholder Information - CITIC Prudential Fund has a fund that entered the top ten circulating shareholders of TuoJing Life, specifically the CITIC Prudential Multi-Strategy Mixed (LOF) A (165531), which acquired 1.2039 million shares, accounting for 0.87% of circulating shares. The estimated floating profit today is approximately 1.5049 million CNY [2]. - The fund was established on June 16, 2017, with a latest scale of 1.245 billion CNY. Year-to-date returns are 40.07%, ranking 1467 out of 8174 in its category; the one-year return is 77.36%, ranking 1081 out of 7981; and since inception, the return is 137.18% [2]. Fund Management - The fund managers of CITIC Prudential Multi-Strategy Mixed (LOF) A are Jiang Feng and Wang Ying. Jiang Feng has a cumulative tenure of 5 years and 153 days, with a total fund asset size of 5.782 billion CNY, achieving a best fund return of 125.39% and a worst return of 2.45% during his tenure [3]. - Wang Ying has a cumulative tenure of 8 years and 211 days, managing a total fund asset size of 3.835 billion CNY, with a best fund return of 49.08% and a worst return of -8.42% during her tenure [3].

Group 1 - The core point of the article is that Tsinghua Tongfang Life Science has announced the receipt of a patent certificate for an invention by the company and its wholly-owned subsidiary, Shanghai Tsinghua Tongfang Diagnostic Technology Co., Ltd [2] Group 2 - The announcement was made on the evening of September 10 [2] - The patent is expected to enhance the company's technological capabilities and competitive position in the life sciences industry [2] - This development may lead to potential growth opportunities for the company in the diagnostic technology sector [2]